Home > MEDIA ADVISORY PUBLIC SCIENTIFIC MEETING WILL EXAMINE FUNDING STRUCTURES FOR STEM CELL RESEARCH AND THERAPIES Stem Cell Agency Organizes Meetings for Governing Board and the Public to Hear Expert Information on Strategic Plan

MEDIA ADVISORY PUBLIC SCIENTIFIC MEETING WILL EXAMINE FUNDING STRUCTURES FOR STEM CELL RESEARCH AND THERAPIES Stem Cell Agency Organizes Meetings for Governing Board and the Public to Hear Expert Information on Strategic Plan

Posted: May 24, 2006

WHO:CIRM President Zach Hall, Ph.D. and Staff

Members of the ICOC

Michael Rudnicki, M.D., Ph.D.
University of Ottawa, Canada

Michael Amos, Ph.D.
National Institute of Standards and Technology

Richard Insel, M.D.
Juvenile Diabetes Research Foundation

Ethan Signer, Ph.D.
High Q Foundation

Jonathan Shestack
Cure Autism Now Foundation

WHAT:The first in a series of public meetings designed for the ICOC and the public to discuss specific topics that are critical to the strategic planning process for CIRM funding.

WHY: On April 24, 2006, the California Institute for Regenerative Medicine (CIRM) formally launched its scientific strategic planning process. The goal is to create a set of priorities and a working plan that will guide the scientific programs of CIRM over the coming years. The plan’s development will involve input from multiple stakeholders—including interviews and a series of public meetings.

The Strategic Planning Advisory Committee, composed of members of the ICOC, other leading scientists, patient advocates, and representatives from the private sector, will meet regularly throughout the six month planning process. The ICOC will devote part of their June and August meetings to discussion on the strategic plan, with a draft anticipated for the October ICOC meeting.

In addition, CIRM will host a series of scientific meetings for the ICOC and the public (tomorrow’s meeting being the first) at which invited speakers will discuss scientific strategies and approaches to funding stem cell science and the development of related therapies that CIRM might consider. Finally, CIRM will conduct a public hearing entirely devoted to obtaining public input.